The global market for Non-Alcoholic Steatohepatitis (NASH) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Drugs.

The Non-Alcoholic Steatohepatitis (NASH) Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Alcoholic Steatohepatitis (NASH) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-Alcoholic Steatohepatitis (NASH) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-Alcoholic Steatohepatitis (NASH) Drugs Market Report

Report Metric	Details
Report Name	Non-Alcoholic Steatohepatitis (NASH) Drugs Market
CAGR	5%
Segment by Type	Vitamin E & Pioglitazone Obeticholic Acid (OCA) Elafibranor Selonsertib & Cenicriviroc
Segment by Application	Hospital Pharmacy Online Provider Retail Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Conatus Pharmaceuticals, Enzo Biochem, Galmed Pharmaceuticals, Genfit, Gilead, Horizon Pharma, Immuron, Intercept Pharmaceuticals, Novo Nordisk
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Non-Alcoholic Steatohepatitis (NASH) Drugs Market report?

Ans: The main players in the Non-Alcoholic Steatohepatitis (NASH) Drugs Market are AstraZeneca, Conatus Pharmaceuticals, Enzo Biochem, Galmed Pharmaceuticals, Genfit, Gilead, Horizon Pharma, Immuron, Intercept Pharmaceuticals, Novo Nordisk

What are the Application segmentation covered in the Non-Alcoholic Steatohepatitis (NASH) Drugs Market report?

Ans: The Applications covered in the Non-Alcoholic Steatohepatitis (NASH) Drugs Market report are Hospital Pharmacy, Online Provider, Retail Pharmacy

What are the Type segmentation covered in the Non-Alcoholic Steatohepatitis (NASH) Drugs Market report?

Ans: The Types covered in the Non-Alcoholic Steatohepatitis (NASH) Drugs Market report are Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor, Selonsertib & Cenicriviroc

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Vitamin E & Pioglitazone

1.2.3 Obeticholic Acid (OCA)

1.2.4 Elafibranor

1.2.5 Selonsertib & Cenicriviroc

1.3 Market by Application

1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Online Provider

1.3.4 Retail Pharmacy

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2020-2031)

2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Region

2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Region (2020-2025)

2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2026-2031)

2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics

2.3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends

2.3.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers

2.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges

2.3.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue

3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2020-2025)

3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue

3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio

3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2024

3.5 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs Head office and Area Served

3.6 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs, Product and Application

3.7 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type

4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2020-2025)

4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2026-2031)

5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application

5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2020-2025)

5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2020-2031)

6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025)

6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2020-2031)

7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025)

7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2020-2031)

8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2020-2031)

9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025)

9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2020-2031)

10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AstraZeneca

11.1.1 AstraZeneca Company Details

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.1.5 AstraZeneca Recent Development

11.2 Conatus Pharmaceuticals

11.2.1 Conatus Pharmaceuticals Company Details

11.2.2 Conatus Pharmaceuticals Business Overview

11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.2.5 Conatus Pharmaceuticals Recent Development

11.3 Enzo Biochem

11.3.1 Enzo Biochem Company Details

11.3.2 Enzo Biochem Business Overview

11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.3.5 Enzo Biochem Recent Development

11.4 Galmed Pharmaceuticals

11.4.1 Galmed Pharmaceuticals Company Details

11.4.2 Galmed Pharmaceuticals Business Overview

11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.4.5 Galmed Pharmaceuticals Recent Development

11.5 Genfit

11.5.1 Genfit Company Details

11.5.2 Genfit Business Overview

11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.5.5 Genfit Recent Development

11.6 Gilead

11.6.1 Gilead Company Details

11.6.2 Gilead Business Overview

11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.6.5 Gilead Recent Development

11.7 Horizon Pharma

11.7.1 Horizon Pharma Company Details

11.7.2 Horizon Pharma Business Overview

11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.7.5 Horizon Pharma Recent Development

11.8 Immuron

11.8.1 Immuron Company Details

11.8.2 Immuron Business Overview

11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.8.5 Immuron Recent Development

11.9 Intercept Pharmaceuticals

11.9.1 Intercept Pharmaceuticals Company Details

11.9.2 Intercept Pharmaceuticals Business Overview

11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.9.5 Intercept Pharmaceuticals Recent Development

11.10 Novo Nordisk

11.10.1 Novo Nordisk Company Details

11.10.2 Novo Nordisk Business Overview

11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction

11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

11.10.5 Novo Nordisk Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Conatus Pharmaceuticals

Enzo Biochem

Galmed Pharmaceuticals

Intercept Pharmaceuticals

Novo Nordisk

List of Tables

Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Vitamin E & Pioglitazone

Table 3. Key Players of Obeticholic Acid (OCA)

Table 4. Key Players of Elafibranor

Table 5. Key Players of Selonsertib & Cenicriviroc

Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2020-2025)

Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2026-2031)

Table 12. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Trends

Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers

Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges

Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints

Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2020-2025)

Table 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2024)

Table 19. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs, Headquarters and Area Served

Table 22. Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs, Product and Application

Table 23. Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Drugs, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2020-2025)

Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2026-2031)

Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2020-2025)

Table 31. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2026-2031)

Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 48. AstraZeneca Company Details

Table 49. AstraZeneca Business Overview

Table 50. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 51. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 52. AstraZeneca Recent Development

Table 53. Conatus Pharmaceuticals Company Details

Table 54. Conatus Pharmaceuticals Business Overview

Table 55. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 56. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 57. Conatus Pharmaceuticals Recent Development

Table 58. Enzo Biochem Company Details

Table 59. Enzo Biochem Business Overview

Table 60. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 61. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 62. Enzo Biochem Recent Development

Table 63. Galmed Pharmaceuticals Company Details

Table 64. Galmed Pharmaceuticals Business Overview

Table 65. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 66. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 67. Galmed Pharmaceuticals Recent Development

Table 68. Genfit Company Details

Table 69. Genfit Business Overview

Table 70. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 71. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 72. Genfit Recent Development

Table 73. Gilead Company Details

Table 74. Gilead Business Overview

Table 75. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 76. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 77. Gilead Recent Development

Table 78. Horizon Pharma Company Details

Table 79. Horizon Pharma Business Overview

Table 80. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 81. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 82. Horizon Pharma Recent Development

Table 83. Immuron Company Details

Table 84. Immuron Business Overview

Table 85. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 86. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 87. Immuron Recent Development

Table 88. Intercept Pharmaceuticals Company Details

Table 89. Intercept Pharmaceuticals Business Overview

Table 90. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 91. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 92. Intercept Pharmaceuticals Recent Development

Table 93. Novo Nordisk Company Details

Table 94. Novo Nordisk Business Overview

Table 95. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product

Table 96. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025) & (US$ Million)

Table 97. Novo Nordisk Recent Development

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

Table 101. Authors List of This Report

List of Figures

Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Picture

Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2024 VS 2031

Figure 4. Vitamin E & Pioglitazone Features

Figure 5. Obeticholic Acid (OCA) Features

Figure 6. Elafibranor Features

Figure 7. Selonsertib & Cenicriviroc Features

Figure 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2024 VS 2031

Figure 10. Hospital Pharmacy Case Studies

Figure 11. Online Provider Case Studies

Figure 12. Retail Pharmacy Case Studies

Figure 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered

Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region: 2024 VS 2031

Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2024

Figure 18. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2024

Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2020-2031)

Figure 22. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2020-2031)

Figure 26. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2020-2031)

Figure 34. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2020-2031)

Figure 42. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2020-2031)

Figure 46. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 50. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 51. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 52. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 53. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 54. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 55. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 56. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 57. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 58. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Coronary Imaging Catheter Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32P14840

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Digital Platform for Chronic Kidney Disease (CKD) Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-20V18395

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Continuous Glucose Monitoring Sensor Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32G20014

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9U20281

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions